AR083798A1 - Inhibidores selectivos de glucosidasas y sus usos - Google Patents
Inhibidores selectivos de glucosidasas y sus usosInfo
- Publication number
- AR083798A1 AR083798A1 ARP110104166A ARP110104166A AR083798A1 AR 083798 A1 AR083798 A1 AR 083798A1 AR P110104166 A ARP110104166 A AR P110104166A AR P110104166 A ARP110104166 A AR P110104166A AR 083798 A1 AR083798 A1 AR 083798A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkenyl
- alkyl
- maximum number
- compounds
- fluorine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
Abstract
Se refiere a compuestos que inhiben selectivamente glucosidasas, a usos de los compuestos y a composiciones farmacéuticas que incluyen los compuestos, y a métodos para tratar enfermedades y trastornos relacionados con el déficit o la sobreexpresión de O-GlcNAcasa, y/o la acumulación o el déficit de O-GlcNAc.Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de dicho compuesto, en la que: cada R es independientemente H o C(O)CH3; R1 y R2 se seleccionan independientemente entre el grupo que consiste en: H, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, -(CH2)n-ciclopropilo y -(CH2)n-ciclobutilo, en el que n es 0, 1, 2, 3 ó 4; o R1 y R2 pueden estar unidos junto con el átomo de nitrógeno al que están unidos para formar azetidina, pirrolidina, piperidina, o isoxazolidina, estando dichos alquilo C1-6, alquenilo C2-6, alcoxi C1-6, -(CH2)n-ciclopropilo, -(CH2)n-ciclobutilo, azetidina, pirrolidina, piperidina o isoxazolidina opcionalmente sustituidos uno hasta el número máximo de sustituyentes con flúor, hidroxi y metilo; R3 se selecciona entre el grupo que consiste en: alquilo C1-8, alquenilo C2-8, alquenilo C2-8, cicloalquilo C3-6, arilo y heteroarilo, cada uno opcionalmente sustituido de uno hasta el número máximo de sustituyentes por flúor y OH; R4 se selecciona entre el grupo que consiste en: H, F, alquilo C1-8, alquenilo C2-8 y alquinilo C2-8, excluyendo cada uno, hidrógeno opcionalmente sustituido de uno hasta el número máximo de sustituyentes por flúor y OH; o R3 y R4 y el átomo de carbono al que están unidos pueden unirse entre sí para formar vinilo o un anillo carbocíclico o heterocíclico de 3 a 7 miembros, conteniendo opcionalmente dicho anillo carbocíclico o heterocíclico de 3 a 7 miembros un doble enlace y estando opcionalmente sustituido de uno hasta el número máximo de sustituyentes por flúor y OH; y R5 se selecciona entre H, F, OH y OC(O)CH3; con la condición de que cuando R4 es F, entonces R5 es distinto de OH y OC(O)CH3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/078528 WO2012061972A1 (en) | 2010-11-08 | 2010-11-08 | Selective glycosidase inhibitors and uses thereof |
| US41859610P | 2010-12-01 | 2010-12-01 | |
| PCT/CN2011/080691 WO2012062157A1 (en) | 2010-11-08 | 2011-10-12 | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083798A1 true AR083798A1 (es) | 2013-03-20 |
Family
ID=46051261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104166A AR083798A1 (es) | 2010-11-08 | 2011-11-08 | Inhibidores selectivos de glucosidasas y sus usos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2637503B1 (es) |
| JP (1) | JP5965407B2 (es) |
| KR (1) | KR101922266B1 (es) |
| AR (1) | AR083798A1 (es) |
| AU (2) | AU2011326186A1 (es) |
| BR (1) | BR112013011441B8 (es) |
| CA (1) | CA2816798C (es) |
| ES (1) | ES2600028T3 (es) |
| MX (1) | MX336611B (es) |
| RU (1) | RU2592285C2 (es) |
| TW (1) | TW201249848A (es) |
| WO (1) | WO2012064680A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009276223B2 (en) | 2008-08-01 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2569291B1 (en) | 2010-05-11 | 2016-04-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012083435A1 (en) * | 2010-12-23 | 2012-06-28 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| KR102054744B1 (ko) | 2011-06-27 | 2019-12-11 | 알렉토스 테라퓨틱스 인크. | 선택적인 글리코시다아제 저해제 및 이의 용도 |
| JP6178843B2 (ja) * | 2012-05-08 | 2017-08-09 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 透過性グリコシダーゼインヒビターおよびその用途 |
| WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| WO2014067003A1 (en) * | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| JP6994819B2 (ja) | 2016-07-26 | 2022-02-04 | 三菱電機株式会社 | 照明具および照明装置 |
| RU2748383C1 (ru) * | 2020-10-21 | 2021-05-25 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ терапии болезни Тея-Сакса и болезни Сандхоффа с помощью генетически модифицированных мезенхимных стволовых клеток человека со сверхэкспрессией β-гексозаминидазы A |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
| JP5154954B2 (ja) | 2005-03-01 | 2013-02-27 | サイモン フレイザー ユニバーシティ | 選択的なグリコシダーゼインヒビター、インヒビターを作製する方法、およびインヒビターの使用 |
| JP5380293B2 (ja) * | 2006-08-31 | 2014-01-08 | サイモン・フレーザー・ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| AU2009276223B2 (en) | 2008-08-01 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110301217A1 (en) | 2008-09-16 | 2011-12-08 | David Jaro Vocadlo | Selective Glycosidase Inhibitors and Uses Thereof |
| CN103930428B (zh) | 2011-08-25 | 2016-05-11 | 默克专利有限公司 | 用作糖苷酶抑制剂的吡喃并[3,2-d][1,3]噻唑 |
-
2011
- 2011-11-07 TW TW100140566A patent/TW201249848A/zh unknown
- 2011-11-08 AU AU2011326186A patent/AU2011326186A1/en not_active Abandoned
- 2011-11-08 AR ARP110104166A patent/AR083798A1/es unknown
- 2011-11-08 JP JP2013537923A patent/JP5965407B2/ja active Active
- 2011-11-08 WO PCT/US2011/059668 patent/WO2012064680A1/en active Application Filing
- 2011-11-08 BR BR112013011441A patent/BR112013011441B8/pt active IP Right Grant
- 2011-11-08 MX MX2013005118A patent/MX336611B/es unknown
- 2011-11-08 CA CA2816798A patent/CA2816798C/en active Active
- 2011-11-08 KR KR1020137014710A patent/KR101922266B1/ko active IP Right Grant
- 2011-11-08 RU RU2013126531/04A patent/RU2592285C2/ru active
- 2011-11-08 ES ES11840448.2T patent/ES2600028T3/es active Active
- 2011-11-08 EP EP11840448.2A patent/EP2637503B1/en active Active
-
2016
- 2016-04-07 AU AU2016202186A patent/AU2016202186B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011326186A8 (en) | 2013-08-01 |
| EP2637503B1 (en) | 2016-09-14 |
| TW201249848A (en) | 2012-12-16 |
| KR20130129974A (ko) | 2013-11-29 |
| ES2600028T3 (es) | 2017-02-06 |
| JP2013541596A (ja) | 2013-11-14 |
| KR101922266B1 (ko) | 2018-11-26 |
| CA2816798C (en) | 2019-02-26 |
| JP5965407B2 (ja) | 2016-08-03 |
| BR112013011441B1 (pt) | 2021-11-09 |
| AU2016202186B2 (en) | 2017-10-12 |
| RU2013126531A (ru) | 2014-12-20 |
| BR112013011441A2 (pt) | 2016-07-19 |
| AU2011326186A1 (en) | 2013-05-23 |
| EP2637503A4 (en) | 2014-04-09 |
| AU2016202186A1 (en) | 2016-04-28 |
| MX336611B (es) | 2016-01-22 |
| MX2013005118A (es) | 2013-07-29 |
| BR112013011441B8 (pt) | 2023-04-18 |
| CA2816798A1 (en) | 2012-05-18 |
| WO2012064680A1 (en) | 2012-05-18 |
| EP2637503A1 (en) | 2013-09-18 |
| RU2592285C2 (ru) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| ECSP066829A (es) | 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR074504A1 (es) | Nucleotidos uracil ciclopropilicos | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| ECSP14013296A (es) | Derivados de etinilo | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| NI200900181A (es) | Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos. | |
| PE20151281A1 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |